Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nitroimidazole - albendazole combination therapy, quinacrine use, and risk factors in nitroimidazole-refractory giardiasis: a prospective multicentre observational study.

BMC infectious diseases·2026
Same author

Evolutionary inference reveals global natural histories and predicted pathways of antimicrobial resistance in Klebsiella pneumoniae.

PLoS biology·2026
Same author

Metabolic reprogramming of the infant gut by bifidobacteria-based probiotics drives exclusion of antibiotic-resistant pathobionts.

Cell reports. Medicine·2026
Same author

Antimicrobial resistance in paediatric bloodstream infections in Tanzania: a longitudinal comparison of two cohort studies.

BMC microbiology·2026
Same author

The Complexity of Translating National Guidelines into Real-World Practice: School Nurses' Health Dialogue with First Graders and Their Caregivers.

The Journal of school nursing : the official publication of the National Association of School Nurses·2026
Same author

Author Correction: Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection.

NPJ vaccines·2026

Related Experiment Video

Updated: Jun 27, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

[Drug resistance in tuberculosis].

Brita Askeland Winje1, Turid Mannsåker, Nina Langeland

  • 1Avdeling for infeksjonsovervåking, Nasjonalt folkehelseinstitutt, Postboks 4404 Nydalen, 0403 Oslo. brita.winje@fhi.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|November 22, 2008
PubMed
Summary

Drug-resistant tuberculosis (DR-TB) poses a global challenge. Early diagnosis and direct observation of medication are key to preventing multidrug-resistant TB (MDR-TB) in Norway.

Related Experiment Videos

Last Updated: Jun 27, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Area of Science:

  • Public Health
  • Infectious Diseases
  • Microbiology

Context:

  • Drug-resistant tuberculosis (DR-TB) is a significant global health threat.
  • The emergence of resistance complicates standard tuberculosis treatment protocols.
  • Understanding DR-TB epidemiology is crucial for effective control strategies.

Purpose:

  • To discuss the causes of drug resistance in tuberculosis.
  • To describe the epidemiology of DR-TB, with a specific focus on Norway.
  • To provide recommendations for managing DR-TB.

Summary:

  • Standard TB treatment is six months; however, incorrect treatment can lead to resistance.
  • Multidrug-resistant TB (MDR-TB) cases in Norway are low but have increased threefold in the last decade, primarily among foreign-born individuals.
  • MDR-TB treatment is prolonged (up to two years), costly, has more side effects, and is associated with lower cure rates and higher fatality, though most cases in Norway are cured.

Impact:

  • Early diagnosis of infectious TB cases is vital.
  • Close patient monitoring, including directly observed therapy, can prevent new MDR-TB cases.
  • Implementing effective management strategies is essential for controlling DR-TB globally and in Norway.